

Francesco ANDREATA, MSc, PhD

Tenure-Track Assistant Professor,
Vita-Salute San Raffaele University
Via Olgettina, 58
20132 Milan
Italy

Born on March 18, 1988



Married, two children (2023 and 2025 parental leave)

Office: (+39) 02 2643 8144

E-mail: francesco.andreata@hsr.it

ORCID ID: <https://orcid.org/0000-0002-5710-3671>

Scopus ID: [55621140800](https://scopus.com/authid/detail.url?authorID=55621140800)

Websites: <https://www.lincoi.it/en/andreata-francesco>
<https://www.hepb.org>

EDUCATION

2017: PhD in immunology (*with honors*), Bio Sorbonne Paris Cité Doctoral School, Paris (France)

2014: European MSc in Genetics (*joint-supervision*), University of Paris-Diderot and Milan-Bicocca

2013: MSc in Biotechnology (*cum laude*), University of Milan-Bicocca, Milan (Italy)

POSITIONS AND TRAINING

2026 – present: *Tenure-track assistant professor*, Faculty of Medicine, Vita-Salute San Raffaele University, Milan.

2024 – 2026: *Associate researcher*, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital, Milan.

*Recipient of the career development award from MERU Foundation for biomedical research

2023 – 2024: *Assistant professor*, Department of Biotechnology and Biosciences, University of Milan Bicocca, Milan.

2018 – 2023: *Postdoctoral fellow*, Dynamic of Immune Responses Laboratory, Department of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital, Milan.

*Recipient of the Fondazione Umberto Veronesi Postdoctoral Fellowship.

2017 – 2018: *Postdoctoral fellow*, Nanomedicine laboratory, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan.

2013 – 2017: *PhD Fellow*, Laboratory for Vascular Translational Science, Bichat Hospital, Paris.

* Recipient of the Île-de-France region – Paris region PhD Grant

LENGUAGES

Italian: Native speaker

English: Advanced (Read, written and spoken)

French: Proficient (Read, written and spoken)

AWARDS AND FELLOWSHIPS

2025: **Recipient of the Italian Science Fund (FIS) Starting Grant**
 2025: “**Antonio Feltrinelli Giovani**” Award in Biology, Accademia Nazionale dei Lincei (Rome)
 2025: **Advisory Board, Emerging Scholars Scientific and Medical (e-SMAB)**, Hepatitis B Foundation
 2025: **Italian Association for the Study of the Liver Award**, for the best Italian publication in hepatology
 2024: **Career Development Award** from Meru Foundation for biomedical research.
 2023: **Mentee of the Italian Society of Immunology (SIICA)** mentoring program
 2021: **San Raffaele University postdoctoral fellowship**
 2020: **San Raffaele University postdoctoral fellowship**
 2019: **Fondazione Umberto Veronesi postdoctoral fellowship**
 2018: **San Raffaele University postdoctoral fellowship**
 2017: **University of Milan postdoctoral fellowship**
 2013: **Île-de-France region – Paris region PhD Grant**

NATIONAL QUALIFICATIONS

2025: **National Scientific Qualification** (Abilitazione Scientifica Nazionale, ASN) for Associate Professor (Seconda Fascia). Academic Discipline 06/A2 (*General Pathology*), Italian Ministry of University and Research (MUR)
 2025: **National Scientific Qualification** (Abilitazione Scientifica Nazionale, ASN) for Associate Professor (Seconda Fascia). Academic Discipline 05/H1 (*Histology*), Italian Ministry of University and Research (MUR)

FUNDING

Principal Investigator of FIS Starting Grant – FIS-2023-01388

Italian Ministry of Health

€1,362,000

2025-2028

MERU Career Development Award

MERU Foundation for Biomedical Research

€375000

2024 – 2029

TEACHING

2025 – present: Assistant professor, Vita-Salute San Raffaele University, Milan.
2023 – 2024: Assistant professor, University of Milan-Bicocca, Milan
2026 – present: Academic supervision of 2 PhD students
2014 – present: Academic supervision of >15 MSc and >20 BSc students
2014 – present: Thesis examiner for >20 undergraduate and graduate theses
2016 – 2017: Instructor (*ATER*) in immunology, University Paris 7, Paris
2014 – 2015: Scientific outreach facilitator, “*Les apprentis chercheurs*” program

EDITORIAL AND REVIEWING ACTIVITY

2023 – 2024: Invited co-guest editor, *FEBS letter*. Special issue
2024: Grant reviewer for *French National Research Agency (ANR)*
2019 – present: Frequent reviewer for *Immunity, PLOS Pathogen, Gut, Nat Rev Gastroenterol Hepatol, Cell*

Reports Medicine, European Journal of Immunology, Journal of Hepatology, STAR Protocols, Cellular Immunology, Scientific Reports, Antiviral Research, Pharmaceutic, Liver International.

PATENTS

2026: Iannacone M, Guidotti LG, Pardi N, Andreata F. Agents and methods for treating viral infections.
US patent application P131195US

INVITED POSITIONS AND SCIENTIFIC MEMBERSHIP

2025 – Present Invited member, *Lincei Interdisciplinary Centre, Accademia Nazionale dei Lincei* (Rome)
2025 – Present Invited member, Emerging Scholars Scientific and Medical Advisory Board (e-SMAB)
 Hepatitis B Foundation (USA)
2025 – Present Member, *Italian Association for the Study of the Liver (AISF)*
2024 – 2025 Invited abstract reviewer, *International HBV Meeting*
2021 – Present Member, *Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)*
2021 – Present Member, *Faculty Opinions*: London, GB. Associate Faculty Member
2018 – 2019 Member, *Cell Culture Italian Association (AICC)*

ACADEMIC-INDUSTRY SCIENTIFIC COLLABORATIONS

Gilead Sciences (Foster City, CA, USA)
Asher Biotherapeutics (South San Francisco, CA, USA)
Bluejay Therapeutics (San Mateo, CA, USA)

ADDITIONAL TRAINING

2024: Laboratory animal science (biology and management of laboratory animals, legislation and ethics), IZS
2023: Spatial transcriptomics training (MERFISH technology), Vizgen
2021: Certified peer reviewer course – Elsevier Researcher Academy (Elsevier)
2016: Animal experimentation course, FELASA category B (Paris-Descartes University), Paris, France
2016: Protein-protein interaction, advanced training (Paris-Diderot University), Paris, France

RESEARCH EXPERTISE

Research Areas: Applied cell biology, tissue immunology, chronic viral infections, cancer immunology, liver immunobiology

Key approaches: Conventional and spectral flow cytometry, FACS sorting (Conventional, Spectral and MACSQuant Tyto), intravital and confocal microscopy, molecular biology, spatial transcriptomics, *in vivo* proximity labelling.

Model Systems: Transgenic mouse models and *in vitro* systems.

Core Skills: Experimental design, grant writing, manuscript preparation and team leadership.

CONGRESSES

2026 Invited Speaker, European of Society Virology: Imaging Viruses. CMSO-CSIC, Madrid, Spain
2026 External Invited Speaker, CNB-CSIC “Severo Ochoa Research Lines” seminar series, Madrid, Spain.
2025 Invited Speaker, BI - IMP - IMBA Meeting, “T cell biology in health and disease”. Vienna, Austria
2025 Invited Speaker, Unlocking the Power of Spatial Genomics. Milan, Italy.
2025 Invited Speaker, Scuola Superiore di Studi Avanzati - La Sapienza, “Translational medicine in

hepatology: from the laboratory to clinical practice". Rome, Italy.

- 2024 Immunothrombosis Symposium 2024. Munich, Germany.
- 2024 Invited Speaker, Hamburg Center for Translational Immunology Symposium. Hamburg, Germany.
- 2024 Bridging Innovation and Translation in T cell Immunotherapy. Munich, Germany.
- 2024 Armenise Harvard Foundation Symposia. Boston, USA.
- 2024 EMBO Immunology Sectoral Meeting 2024. Zürich, Switzerland.
- 2023 Workshop: "Tools offered by BBMRI, EATRIS, ECRIN to support the construction and development of European projects" – Second Edition. Istituto Superiore di Sanità, Rome, Italy.
- 2023 International HBV meeting. Kobe, Japan. (Oral communication)
- 2023 SIPMeT Young Scientist Meeting 2023. Parma, Italy.
- 2023 Italian Association of Immunology and Allergology (SIICA) congress. May 2023, Verona, Italy
- 2022 International HBV meeting. Paris, France. (Oral communication)
- 2021 European Congress of Immunology (ECI). September 2021. (Oral communication)
- 2019 Pathogen immunity and signaling (EMBO), Oxford, United Kingdom.
- 2018 Interaction between nanomaterials and the immune system: medical exploitations and safety issues, Milan, Italy.
- 2016 International Congress of Immunology, Melbourne, Australia. August 2016. (Oral communication)
- 2015 GREMI Meeting on Vascular inflammation. Paris, France.
- 2015 Gordon Research Seminar and Gordon Research Conference in Atherosclerosis Sunday River in Newry (ME), United States.
- 2014 Nouvelle Société Française d'Athérosclérose congress. Biarritz, France. (Oral communication)
Winner of the competition for young researchers
- 2013 Cardiac Regeneration and Vascular Biology. Venice, Italy.

PUBLICATIONS (31 Documents; 11 First authorships; Total citations >1760; h-index >17)

- 1) Marotta D, Perucchini C, Grillo M, Fumagalli V, Di Lucia P, Ravà M, Giustini L, Malpighi C, D'Uonno G, Rixon J, Mouro V, Stachura N, **Andreata F**, Donnici L, Scavone M, Inverso D, De Francesco R, Gaya M, Ruggeri Z.M., Podda G, Guidotti L.G., Iannacone M, De Giovanni M. **Platelet-derived serotonin drives age-related pathology in SARS-CoV-2 infection**. 2026 (Submitted)
- 2) Razafiarison J, Alzaid F, Leveau C, Tonui D, Diedisheim M, Bied M, Silvin A, Kong W.T., Anagnostopoulos G, Laveille A, Dunsmore G, Signolle N, Hammoutene A, Laura C, Garcia-Manteiga J.M., **Andreata F**, Ficht X, Weidner D, Guo W, Boissonnas W, Greter M, Liu Z, Chakarov S, Uderhardt S, Paradis V, Iannacone I, Venteclef N, Ginhoux F, *Blériot C. **CD36+ Kupffer cells control postprandial lipid clearance and fuel metabolic dysfunction-associated steatotic liver diseases**. 2026 (Submitted)
- 3) Giacca G, Buccarello G, Bresesti C, Breggion S, Notaro M, Russo S, D'Alessio F, Chiaro J, Branca R.M.M., Shrung K.R, Lehtiö J, Monti M, Trippitelli F, Potenza A, Ruggiero E, **Andreata F**, Rancoita P.M.V., Iannacone M, Bonini C, Naldini L, Cerullo V, Squadrito M.L. **Circulating tumor antigens drive immune suppression and disease progression**. 2026 (Submitted)
- 4) David B.A. *, **Andreata F***, Bleriot C*, Ginhoux F, Iannacone M, Kubes P. **Kupffer cells in liver homeostasis and disease: from immune sentinels to metabolic gatekeepers**. (* Co-first authorship) *Nat Rev Immunol*. 2026
- 5) **Andreata F**, Granucci F, Marongiu L. Dendritic cells in focus: **mapping functional diversity through technological innovation**. *FEBS Letters*. 2025
- 6) Panetti C, Dätwyler R, Moncsek A, Patikas N, Agrafiotis A, Tang A, **Andreata F**, Fumagalli V, De Lima J, King CG, Vasanthakumar A, Iannacone M, Kallies A, Yermanos A, Hemberg M, Joller N. **The co-inhibitory receptor TIGIT promotes tissue protective functions in T cells**. *Nat Immunol*. 2025
- 7) **Andreata F***, Laura C*, Ravà M*, Krüger C*, Ficht X*, Kawashima K*, Beccaria G.C*, Moalli F, Fumagalli V, Partini B, Nosetto G, Di Lucia P, Montali I, Beccaria C, Garcia-Manteiga J. M, Bono E, Giustini L, Perrucchini C, Venzin V, Ranucci S, Genua M, Ostuni R, Lugli E, De Giovanni M, Isogawa

- M, Ferrari C, Boni C, Fisicaro P., Guidotti L. G, Iannacone M. **Therapeutic potential of co-signaling receptor modulation in hepatitis B.** (* Co-first authorship). *Cell*. 2024
- 8) **Andreata F**, Iannacone M. **The hidden strength of CD8⁺ T cells in chronic hepatitis B.** *Nat Immunol*. 2024
 - 9) **Andreata F***, Moynihan K. D*, Fumagalli V*, Di Lucia P, Fumagalli V, Pappas D. C, Kawashima K, Ni I, Bessette P. H, Perucchini C, Bono E, Giustini L, Nguyen H. C, Chin S. M, Yeung Y. A, Gibbs C. S, Djuretic I, Iannacone M. **CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus.** (* Co-first authorship). *Sci Transl Med*. 2024
 - 10) Venzin V, Beccaria C, **Andreata F**, Fumagalli V, Iannacone M. **Intrahepatic Immunity to Hepatitis B virus.** *J Hepatol*. 2024
 - 11) Kawashima K, **Andreata F**, Beccaria C, Iannacone M. **Priming and maintenance of adaptive immunity in the liver.** *Annu Rev Immunol*. 2024
 - 12) Sevieri M*, **Andreata F***, Mainini F, Signati L, Piccotti L, Truffi M, Bonizzi A, Sitia L, Pigliacelli C, Morasso C, Tagliaferri B, Corsi F, Mazzucchelli S. **Impact of doxorubicin-loaded ferritin nanocages (FerOX) vs. free doxorubicin on T lymphocytes: a translational clinical study on breast cancer patients undergoing neoadjuvant chemotherapy.** (* Co-first authorship) *J Nanobiotechnology*. 2024
 - 13) **Andreata F***, Clément M*, Benson R. A, Hadchouel J, Procopio E, Even G, Vorbe J, Benadda S, Ollivier V, Ho-Tin-Noé B, Le Borgne M, Maffia P, Nicoletti A, Caligiuri G. **CD31 signaling promotes the detachment at the uropod of extravasating neutrophils allowing their migration to sites of inflammation.** (* Co-first authorship) *Elife*. 2023
 - 14) Iannacone M, **Andreata F**, Guidotti L. **Immunological insights in the treatment of chronic hepatitis B.** *Curr Opin Immunol*. 2022
 - 15) Fumagalli V, Venzin V, Di Lucia P, Moalli F, Ficht X, Ambrosi G, Giustini L, **Andreata F**, Grillo M, Magini D, Ravà M, Friedrich C, Fontenot J.D, Bousso P, Gilmore S.A, Khan S, Baca M, Vivier E, Gasteiger G, Kuka M, Guidotti L.G, Iannacone M. **Group 1 ILCs regulate T cell-mediated liver immunopathology by controlling local IL-2 availability.** *Sci Immunol*. 2022
 - 16) De Simone G*, **Andreata F***, Bleriot C*, Fumagalli V*, Laura C, Garcia-Manteiga J, Di Lucia P, Gilotto S, Ficht X, De Ponti F, Bono E, Giustini L, Ambrosi G, Mainetti M, Zordan P, Bénéchet A, Ravà M, Chakarov S, Moalli F, Bajenoff M, Guidotti L.G, Ginhoux F, Iannacone M. **Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming.** (* Co-first authorship) *Immunity*. 2021
 - 17) Blériot C, Barreby E, Dunsmore G, Ballaire R, Chakarov S, Ficht X, De Simone G, **Andreata F**, Fumagalli V, Guo W, Wan G, Gessain G, Khalilnezhad A, Zhang XM, Ang N, Chen P, Morgantini C, Azzimato V, Kong WT, Liu Z, Pai R, Lum J, Shihui F, Low I, Xu C, Malleret B, Kairi MFM, Balachander A, Cexus O, Larbi A, Lee B, Newell EW, Ng LG, Phoo WW, Sobota RM, Sharma A, Howland SW, Chen J, Bajenoff M, Yvan-Charvet L, Venteclef N, Iannacone M, Aouadi M, Ginhoux F. **A subset of Kupffer cells regulates metabolism through the expression of CD36.** *Immunity*. 2021
 - 18) Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis R, Andrä I, **Andreata F**, (...), Yang J. **Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition).** *Eur J Immunol*. 2021
 - 19) **Andreata F**, Blériot C, Di Lucia P, De Simone G, Fumagalli V, Ficht X, Beccaria CG, Kuka M, Ginhoux F, Iannacone M. **Isolation of mouse Kupffer cells for phenotypic and functional studies.** *STAR Protoc*. 2021
 - 20) **Andreata F***, Bonizzi A*, Sevieri M, Truffi M, Monieri M, Sitia L, Silva F, Sorrentino L, Allevi R, Zerbi P, Marchini B, Longhi E, Ottria R, Casati S, Vanna R, Morasso C, Bellini M, Prosperi D, Corsi F, Mazzucchelli S. **Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2⁺ murine breast cancer model.** (* Co-first authorship) *Sci Rep*. 2020
 - 21) Bénéchet AP, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, Fumagalli V, Lusito E, Moalli F, Bianchessi V, **Andreata F**, Zordan P, Bono E, Giustini L, Bonilla WV, Bleriot C, Kunasegaran K, Gonzalez-Aseguinolaza G, Pinschewer DD, Kennedy PTF, Naldini L, Kuka M, Ginhoux F, Cantore A, Bertoletti A, Ostuni R, Guidotti L.G, Iannacone M. **Dynamics and genomic landscape of CD8⁺ T cells undergoing hepatic priming.** *Nature*. 2019

- 22) Vigne J, Bay S, Aid-Launais R, Pariscoat G, Rucher G, Sénémaud J, Truffier A, Anizan N, Even G, Ganneau C, **Andreata F**, Le Borgne M, Nicoletti A, Le Guludec D, Caligiuri G, Rouzet F. **Cleaved CD31 as a target for in vivo molecular imaging of inflammation.** *Sci Rep.* 2019
- 23) **Andreata F***, Syvannarath V*, Clement M*, Delbosc S, Guedj K, Fornasa G, Khallou-Laschet J, Morvan M, Even G, Procopio E, Gaston AT, Le Borgne M, Deschamps L, Nicoletti A, Caligiuri G. **Macrophage CD31 Signaling in Dissecting Aortic Aneurysm.** (* Co-first authorship) *J Am Coll Cardiol.* 2018
- 24) Chen CC, Pouliquen E, Broisat A, **Andreata F**, Racapé M, Bruneval P, Kessler L, Ahmadi M, Bacot S, Saison-Delaplace C, Marcaud M, Van Huyen JD, Loupy A, Villard J, Demuylder-Mischler S, Berney T, Morelon E, Tsai MK, Kolopp-Sarda MN, Koenig A, Mathias V, Ducreux S, Ghezzi C, Dubois V, Nicoletti A, Defrance T, Thaunat O. **Endothelial chimerism and vascular sequestration protect pancreatic islet grafts from antibody-mediated rejection.** *J Clin Invest.* 2018
- 25) Hoang QT, Nuzzo A, Louedec L, Delbosc S, **Andreata F**, Khallou-Laschet J, Assadi M, Montravers P, Longrois D, Corcos O, Caligiuri G, Nicoletti A, Michel JB, Tran-Dinh A. **Peptide binding to cleaved CD31 dampens ischemia/reperfusion-induced intestinal injury.** *Intensive Care Med Exp.* 2018
- 26) Sannier A, Stroumza N, Caligiuri G, Le Borgne-Moynier M, **Andreata F**, Senemaud J, Louedec L, Even G, Gaston AT, Deschildre C, Couvelard A, Ou P, Cheynier R, Nataf P, Dorent R, Nicoletti A. **Thymic function is a major determinant of onset of antibody-mediated rejection in heart transplantation.** *Am J Transplant.* 2017
- 27) El Khoury P, Roussel R, Fumeron F, Abou-Khalil Y, Velho G, Mohammedi K, Jacob MP, Steg PG, Potier L, Ghaleb Y, El Bitar S, Ragot S, **Andreata F**, Caligiuri G, Hadjadj S, Boileau C, Marre M, Abifadel M, Varret M, Hansel B. **Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.** *Diabetes Obes Metab.* 2017
- 28) Clement M, Guedj K, **Andreata F**, Morvan M, Bay L, Khallou-Laschet J, Gaston AT, Delbosc S, Alsac JM, Bruneval P, Deschildre C, Le Borgne M, Castier Y, Kim HJ, Cantor H, Michel JB, Caligiuri G, Nicoletti A. **Control of the T follicular helper-germinal center B-cell axis by CD8⁺ regulatory T cells limits atherosclerosis and tertiary lymphoid organ development.** *Circulation.* 2015
- 29) Clement M, Fornasa G, Loyau S, Morvan M, **Andreata F**, Guedj K, Khallou-Laschet J, Larghi P, Le Roux D, Bismuth G, Chiocchia G, Hivroz C, Newman DK, Nicoletti A, Caligiuri G. **Upholding the T cell immune-regulatory function of CD31 inhibits the formation of T/B immunological synapses in vitro and attenuates the development of experimental autoimmune arthritis in vivo.** *J Autoimmun.* 2015
- 30) Guedj K, Khallou-Laschet J, Clement M, Morvan M, Delbosc S, Gaston AT, **Andreata F**, Castier Y, Deschildre C, Michel JB, Caligiuri G, Nicoletti A. **Inflammatory micro-environmental cues of human atherotrombotic arteries confer to vascular smooth muscle cells the capacity to trigger lymphoid neogenesis.** *PLoS One.* 2014
- 31) Mazzucchelli S, Colombo M, Verderio P, Rozek E, **Andreata F**, Galbiati E, Tortora P, Corsi F, Prosperi D. **Orientation-Controlled Conjugation of HALO-Fused Homing Peptides to Multifunctional Nanoparticles for Specific Recognition of Cancer Cells.** *Angew Chem Int Ed Engl.* 2013

PERSONAL STATEMENT

My research focuses on elucidating the cellular and molecular mechanisms regulating innate and adaptive immune responses. During my PhD at the Bio Sorbonne Paris Cité doctoral school in Paris, I investigated CD31, an ITIM-bearing receptor, and its role in neutrophil biology. By developing novel Cre-Lox mouse models, I demonstrated that CD31 ITIM signaling regulates integrin closure in neutrophils, enabling their migration to inflammatory sites.

In 2018, I returned to Italy and joined the lab of Prof. Matteo Iannacone at IRCCS San Raffaele Hospital, whose mentorship has been instrumental in shaping my scientific development and in consolidating my transition toward independent research. Within his group, I studied CD8⁺ T cell responses in the liver using mouse models of HBV pathogenesis, in close collaboration with Prof. Luca Guidotti. Together, we demonstrated that hepatocellular priming induces a dysfunctional CD8⁺ T cell program distinct from classical exhaustion. These intrahepatic T cells, although resistant to PD-1 blockade, can be reinvigorated by IL-2 through a mechanism dependent on a newly identified subset of Kupffer cells capable of cross-presenting hepatocellular antigens. This work led to key publications and initiated collaborations with pharmaceutical companies for the preclinical development of immunomodulatory therapies.

In 2024, I received the Career Development Award from the MERU Foundation and, in 2025, a Starting Grant from the Italian Science Fund (FIS), which allowed me to establish my own independent line of research. My work has also been recognized with prestigious awards such as the “Antonio Feltrinelli Giovani” Prize in Biology from the Accademia Nazionale dei Lincei and appointment to the Emerging Scholars Scientific and Medical Advisory Board (e-SMAB) of the Hepatitis B Foundation.

I am currently a tenure-track (RTT) Assistant Professor at Vita-Salute San Raffaele University, where I lead a research team investigating how dysfunctional immune responses in tissues can be reprogrammed to enhance their effectiveness against chronic infections and cancer. Our work aims to apply biological knowledge of complex immune systems to develop strategies to improve immune function. To achieve this, I combine experimental immunology with spatial biology approaches to investigate how tissue architecture and cellular niches shape cellular biology.

I am deeply committed to teaching undergraduate and graduate students at Vita-Salute San Raffaele University, mentoring young researchers, and fostering knowledge transfer between academia, industry, and the nonprofit sector. I regularly participate in international conferences, serve on editorial boards for specialized journals, and contribute to the broader immunology community through active participation in scientific societies.

Milan, 01/03/2026

